Press release on the recall of Philips Respironics medical device for continuous positive airway pressure (CPAP) and non-invasive ventilation (NIV) APPQ working committee: Jean‐Louis Aubé (CHUS), Caroline Minville (IUCPQ), Vincent Jobin (CHUM), Marta Kaminska, (MUHC), Mark Palayew (JGH) APPQ position:
The information currently available regarding the recall cited in the title is insufficient to make clear recommendations on how to deal with this situation of global involvement. (See appendix 1 for communication to the Philips doctor). It is common opinion that while waiting for more information on the conduct to adopt, we recommend that you refer to the press release issued by the “American Thoracic Society, ATS” which supports an approach based on patient safety. Here is the link: Recommendations for Sleep and Critical Care Medicine Professionals Regarding Philips Recall Notice (thoracic.org): It is recommended that patients on CPAP or NIV who have severe breathing difficulties, or who were very drowsy in the day before their treatment, or have significant comorbidities at the pulmonary, cardiovascular or neurological level or who work in critical positions a/n safety (professional drivers, pilots, heavy machinery operators) we recommend not to stop treatment and then discuss with their doctor. For other patients, Respironics suggests discontinuing treatment and the provider or physician should be contacted for an opinion on whether or not to continue treatment. Several questions remain unanswered for the moment concerning the risk in hospitalized patients or at home with these devices, the management of repairs / replacements, repair times, sleep laboratories and the roles of each in the disclosure and transmission of information. to patients. Discontinuing the use of ozone-based cleaners is recommended as it could potentially accelerate the degradation of the appliance foam. (Potential Risks Associated With The Use of Ozone and Ultraviolet (UV) Light Products for Cleaning CPAP Machines and Accessories: FDA Safety Communication | FDA) An advisory regarding the risks of potentially hazardous chemicals and volatile organic compounds (VOCs) has been asked the Association of Specialists in Preventive Medicine of Quebec (ASMPQ). An update of the press release will be sent to you as soon as the information available allows us to establish clear actions to take in the face of this crisis. The risk of stopping therapy could be much greater than the risk of continuing it. Clinical judgment must prevail in any course of action in this unique situation.